Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 19/20 | 0.50 |
| ▸ | HTR2A | P28223 | 18/20 | 0.50 |
| ▸ | HTR2B | P41595 | 8/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4783474 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL4780643 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL31079689 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL4728672 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL22556167 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL4783478 | 1.00 | HTR2C (0.50) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL5785622 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL5785530 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| Hydrochloric Acid SCHEMBL5785624 | 0.99 | HTR2C (0.49) | HTR2CHTR2AHTR2BHTR1AADRA2A | |
| SCHEMBL14259248 | 0.91 | HTR2C (0.38) | HTR2CHTR2AHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033183-A1 | PROCESS FOR PREPARING PYRANOINDAZOLE SEROTONERGIC RECEPTOR AGONISTS | ALCON MANUFACTURING, LTD. (US) | 2008-02-07 | — | — | US | claimed |
| US-20060073172-A1 | Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure | SCHNEIDER L W | 2006-04-06 | — | — | US | claimed |
| EP-1392292-B1 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2006-03-01 | — | — | EP | claimed |
| US-6881749-B2 | Pyranoindazoles and their use for the treatment of glaucoma | ALCON, INC. (CH) | 2005-04-19 | — | — | US | claimed |
| EP-1513521-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2005-03-16 | — | — | EP | claimed |
| EP-1392658-A4 | NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2004-10-13 | — | — | EP | claimed |
| EP-1392292-A4 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON INC (CH) | 2004-08-11 | — | — | EP | claimed |
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | claimed |
| US-20040106597-A1 | Novel fused indazoles and indoles and their use for the treatment of glaucoma | NOVARTIS AG (CH) | 2004-06-03 | — | — | US | claimed |
| EP-1392658-A1 | NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| EP-1392292-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | Alcon, Inc. (CH) | 2004-03-03 | — | — | EP | claimed |
| US-6696476-B2 | SUCH AS 1-(2-AMINOPROPYL)-1,7,8,9-TETRAHYDRO-PYRANO(2,3-G)-INDAZOL-8-OL; LOWERING AND CONTROLLING INTRAOCULAR PRESSURE | ALCON, INC. (CH) | 2004-02-24 | — | — | US | claimed |
| WO-2003101379-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2003-12-11 | — | — | WO | claimed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | claimed |
| WO-2002098860-A1 | NOVEL FUSED INDAZOLES AND INDOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | claimed |
| WO-2002098350-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | claimed |
| US-20080058533-A1 | PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE | ALCON, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| WO-2008028021-A2 | PYRANOINDAZOLE CYCLIC CARBONATES AND THEIR USE | ALCON, INC. (CH) | 2008-03-06 | — | — | WO | disclosed |
| US-20030171418-A1 | Reducing or controlling eye pressure | NOVARTIS AG (CH) | 2003-09-11 | — | — | US | disclosed |
| WO-2002098350-A2 | PYRANOINDAZOLES AND THEIR USE FOR THE TREATMENT OF GLAUCOMA | ALCON, INC. (CH) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106609-A1 | Pyranoindazoles and their use for the treatment of glaucoma | PDE3A, CYP11B2, PDE3B | HTR2C 2288/4885HTR2A 2774/4885HTR2B 2644/4885 |
| US-20030171418-A1 | Reducing or controlling eye pressure | PDE3A, PDE3B, QDPR | HTR2C 1978/4885HTR2A 1849/4885HTR2B 1919/4885 |
| US-20040106597-A1 | Novel fused indazoles and indoles and their use for the treatment of glaucoma | IDO1, IDO2, GLI1 | HTR2C 958/4885HTR2A 947/4885HTR2B 1247/4885 |
| US-20080033183-A1 | PROCESS FOR PREPARING PYRANOINDAZOLE SEROTONERGIC RECEPTOR AGONISTS | HTR3A, HTR3C, HTR7 | HTR2C 7/4885HTR2A 13/4885HTR2B 11/4885 |
| US-20080058533-A1 | PYRANOINDAZOLE CYCLIC CARBONATES AND METHODS OF USE | CA3, CYP11B2, PDXK | HTR2C 1301/4885HTR2A 3676/4885HTR2B 2562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.